Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2015-05-26 Management Reports
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Shareholder Newsletter 6 pages 450.8KB
Management Reports Classification · 95% confidence The document is a detailed letter from the CEO and a science update focusing on the company's progress in drug development, collaborations, licensing agreements, and scientific data related to breast cancer programs. It includes substantive discussion of research results, strategic partnerships, and future development plans. The length is substantial (15,000 characters), and it contains detailed scientific and business information rather than just an announcement or summary. There is no indication that this is a transcript of a call, a voting result, or a regulatory filing. It is not a short announcement or a certification letter. The content aligns with a comprehensive report on company activities and scientific progress, typical of an Annual Report or a Management Discussion and Analysis. However, since it lacks full financial statements and focuses heavily on scientific progress and strategic updates, it fits best as a Management Report (MDA) rather than a full Annual Report (10-K). Therefore, the most appropriate classification is Management Reports (MDA).
2015-05-26 English
Appendix 3B 11 pages 120.4KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form submitted to the ASX (Australian Securities Exchange), which is used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content includes detailed information about the class of securities issued (unlisted options), number of securities, terms, issue price, purpose of the issue, and security holder approvals. It also discusses the quotation of securities on the ASX. This type of document is a capital/financing update rather than a full financial report or other types of filings. It is not an annual report, earnings release, or management report, but specifically an announcement of new securities issuance and related capital structure changes.
2015-04-30 English
Appendix 4C - quarterly 4 pages 29.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarter ended 31 March 2015, indicating it is a quarterly financial report. The content includes actual financial statements and substantive financial data, not just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR). The document length is 6568 characters, which is sufficient for a full report rather than a brief announcement. Therefore, the appropriate classification is IR with high confidence. Q3 2015
2015-04-29 English
CEO Interview and Article 1 page 20.5KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Phylogica Ltd dated 15 April 2015, providing information about third-party coverage (an article in Bioshares) and an interview with the CEO available on the company's website. It does not contain any financial data, regulatory filings, or detailed reports. It is essentially a regulatory announcement informing investors about external coverage and media interviews. Given the short length (868 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-04-14 English
Investor Presentation 37 pages 2.5MB
Investor Presentation Classification · 100% confidence The document is titled 'Phylogica 2015 Investor Presentation' and contains detailed slides about the company's technology, corporate strategy, scientific developments, partnerships, and financial highlights. It is structured as a presentation with multiple pages of content aimed at investors, including strategic objectives, market positioning, and licensing deals. There is no indication that this is a formal regulatory filing like an annual or quarterly report, audit report, or earnings release. The content is typical of an investor presentation designed to inform and attract investors by showcasing the company's business and technology. Therefore, the document fits the category of an Investor Presentation (IP). The document length is substantial (15,000 characters), supporting that it is a full presentation rather than a brief announcement or summary.
2015-04-08 English
Phylogica licenses peptides to UK company 3 pages 84.6KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a transaction between Phylogica Limited and PhoreMost Limited involving licensing and equity stake acquisition. It details the terms of the agreement, strategic rationale, and background information about both companies and their technologies. There are no financial statements, regulatory form references, or detailed financial performance data. The content focuses on a business transaction and partnership rather than financial results, management changes, or regulatory filings. This fits best under Capital/Financing Update (CAP) as it involves equity stake acquisition and licensing agreements related to company financing and strategic partnerships.
2015-04-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.